医学部 循環器内科学
  1. Researcher List
  2. Takashi Muramatsu

Takashi Muramatsu

  (村松 崇)

Profile Information

Affiliation
Associate Professor, School of Medicine, Faculty of Medicine, Fujita Health University
Degree
Ph.D.(Mar, 2011, Nagoya University, Nagoya, JP)
Ph.D.(May, 2015, Erasmus University, Rotterdam, NL)
Contact information
takamfujita-hu.ac.jp
J-GLOBAL ID
201501016252332081
researchmap Member ID
7000012709

Research Interests

 5

Research Areas

 2

Education

 3

Papers

 133
  • Simone Fezzi, Bruno Scheller, Bernardo Cortese, Fernando Alfonso, Raban Jeger, Antonio Colombo, Michael Joner, Eun-Seok Shin, Franz X Kleber, Azeem Latib, Tuomas T Rissanen, Simon Eccleshall, Flavio Ribichini, Ling Tao, Bon-Kwon Koo, Alaide Chieffo, Junbo Ge, Juan F Granada, Hans-Peter Stoll, Christian Spaulding, Rafael Cavalcante, Alexandre Abizaid, Takashi Muramatsu, Konstantinos Dean Boudoulas, Ron Waksman, Roxana Mehran, Donald E Cutlip, Mitchell W Krucoff, Gregg W Stone, Scot Garg, Yoshinobu Onuma, Patrick W Serruys
    European heart journal, 46(26) 2498-2519, Jul 7, 2025  
    The Drug Coated Balloon Academic Research Consortium project originated from the lack of standardization and comparability between studies using drug-coated balloons in the treatment of obstructive coronary artery disease. This document is a collaborative effort between academic research organizations and percutaneous coronary intervention societies in Europe, the USA, and Asia. This consensus sought to standardize study designs and endpoints for clinical trials involving drug-coated balloons, including defining angiographic, intravascular, and non-invasive imaging methods for lesion assessment, alongside considerations for post-revascularization pharmaco-therapy. The concept of 'blended therapy', which advocates for combining device strategies, is also discussed. This paper delineates study types, endpoint definitions, follow-up protocols, and analytical approaches, aiming to provide consistency and guidance for interventional cardiologists and trialists.
  • Masataka Yoshinaga, Takashi Muramatsu, Hiroki Higami, Kenya Nasu
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 106(1) 120-127, Jul, 2025  
    We present a novel, simple, and low-cost "side-hole" technique for a patient with ST-segment elevation myocardial infarction (STEMI) caused by an occlusion of an anomalous origin of the culprit coronary artery (AOCCA). In a case where standard guiding catheters failed to engage the anomalous left coronary artery (LCA), we created an approximately 3 mm side-hole near the tip of a 5 Fr diagnostic catheter and then introduced a guidewire and microcatheter directly into the anomalous left main trunk (LMT). Subsequently, we withdrew this diagnostic catheter and exchanged it for a guiding catheter over the guide wire, enabling rapid primary PCI. This approach facilitated rapid wire passage, minimized additional device use, and helped reduce overall reperfusion time. It may be especially useful in urgent STEMI cases where a suitable guiding catheter for AOCCA lesions cannot be readily identified.
  • Masato Nakamura, Nehiro Kuriyama, Yutaka Tanaka, Seiji Yamazaki, Tomohiro Kawasaki, Takashi Muramatsu, Kazushige Kadota, Takashi Ashikaga, Akihiko Takahashi, Satoru Otsuji, Kenji Ando, Masaru Ishida, Shigeru Nakamura, Yoshiaki Ito, Raisuke Iijima, Gaku Nakazawa, Junya Shite, Junko Honye, Junya Ako, Hiroyoshi Yokoi, Ken Kozuma, Hiromasa Otake, Kazuho Masumura, Tomomi Yamada, Yohei Sotomi
    Cardiovascular intervention and therapeutics, 40(3) 553-564, Jul, 2025  
    Evaluation of calcified lesions by intravascular imaging has revealed that atherectomy devices have only limited impact. However, subsequent use of coronary intravascular lithotripsy (IVL) may increase treatment effectiveness without increasing risk of complications. This study was designed to evaluate the safety and effectiveness of IVL use after atherectomy in severely calcified coronary lesions as pre-treatment for drug-eluting stents (DES). The Dual-Prep registry is a multicenter, prospective registry of consecutive image-guided percutaneous coronary interventions (PCI). The primary effectiveness and safety endpoints were procedural success (residual stenosis < 50% by quantitative coronary angiography) without an in-hospital major adverse cardiac event (MACE) and 30-day freedom from MACE, respectively. Baseline vessel calcification score and final DES expansion were evaluated by optical coherence tomography (OCT). A total of 118 patients with 120 lesions were enrolled at 20 sites. The calcification score of lesions after atherectomy by core-lab assessment was 4.0 in all cases. Rotational atherectomy was applied prior to IVL in 83.9% cases with mean burr size of 1.57 ± 0.20 mm; IVL was subsequently successfully delivered in all cases (mean balloon diameter 3.02 ± 0.45 mm), followed by DES deployment (mean diameter 3.19 ± 0.51 mm, length of 36.3 ± 16.0 mm). The primary efficacy and safety endpoints were met in 98.3% and 98.3% of cases, respectively. A DES expansion index < 0.8 was seen in 42.2%, and an eccentricity index < 0.7 was not observed in any patient. In severely calcified lesions, image-guided atherectomy followed by IVL lesion preparation demonstrated high procedural success rates and satisfactory non-eccentric stent expansion. This approach may be considered for lesions where an 'IVL-first' strategy may not be feasible. jRCT1032230384 (Oct 7, 2023).
  • Takashi Muramatsu
    AsiaIntervention, 11(2) e99-e100, Jul, 2025  
  • Masataka Yoshinaga, Takashi Muramatsu, Yuto Kondo, Akane Miyazaki, Taishi Fukushima, Yoshihiro Sobue, Yoshinori Narukawa, Wakaya Fujiwara, Kenya Nasu, Eiichi Watanabe
    JACC. Case reports, 30(12) 103526-103526, May 28, 2025  
    OBJECTIVE: This study highlights a case in which we performed a complex percutaneous coronary intervention on a 60-mm chronic total occlusion lesion with a remarkably low radiation dose by using the SPOT region of interest (SPOT ROI) function available on the Alphenix Evolve Edition X-ray system (Canon Medical Systems). KEY STEPS: Fluoroscopy was conducted exclusively using SPOT ROI from the start of guiding catheter engagement. The wire successfully traversed the chronic total occlusion lesion with SPOT ROI. Despite a fluoroscopy time of 71 min, the total radiation dose was kept at 990 mGy, remaining <1 Gy. POTENTIAL PITFALLS: The SPOT ROI function is only available on the Alphenix Evolve Edition X-ray system and cannot be used with other X-ray equipment. TAKE-HOME MESSAGE: This case suggests that SPOT ROI can be leveraged to safely reduce radiation during complex percutaneous coronary intervention.
More

Misc.

 128
  • TsungYing Tsai, Kotaro Miyashita, Akihiro Tobe, Takashi Muramatsu, Yuki Ishibashi, Gaku Nakazawa, Kuniaki Takahashi, Takayuki Okamura, Yosuke Miyazaki, Masato Nakamura, Norihiro Kogame, Taku Asano, Yuki Katagiri, Scot Garg, Christos Bourantas, Patrick Serruys, Yoshinobu Onuma
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 84(18) B172-B172, Oct 29, 2024  
  • 西村豪人, 石井潤一, 石原裕也, 中村和広, 北川文彦, 坂口英林, 河合秀樹, 村松崇, 原田将英, 山田晶, 谷澤貞子, 成瀬寛之, 皿井正義, 簗瀬正伸, 渡邉英一, 尾崎行男, 井澤英夫
    日本循環器学会学術集会(Web), 88th(6) 531-544, 2024  
    We investigated the prognostic value of cardiac myosin-binding protein C (cMyC), a novel cardiospecific marker, both independently and in combination with N-terminal pro-B-type natriuretic peptide (NT-proBNP), for predicting 6-month all-cause mortality in patients without acute coronary syndrome (ACS) treated at medical (nonsurgical) cardiac intensive care units (CICUs). Admission levels of cMyC, high-sensitivity cardiac troponin T (hs-cTnT), and NT-proBNP were measured in 1032 consecutive patients (mean age; 70 years) without ACS hospitalized acutely in medical CICUs for the treatment of cardiovascular disease. Serum cMyC was closely correlated with hs-cTnT and moderately with NT-proBNP (r = 0.92 and r = 0.49, respectively, p < 0.0001). During the 6-month follow-up period after admission, there were 109 (10.6%) all-cause deaths, including 72 cardiovascular deaths. Both cMyC and NT-proBNP were independent predictors of 6-month all-cause mortality (all p < 0.05). Combining cMyC and NT-proBNP with a baseline model of established risk factors improved patient classification and discrimination beyond any single biomarker (all p < 0.05) or the baseline model alone (both p < 0.0001). Moreover, patients were divided into nine groups using cMyC and NT-proBNP tertiles, and the adjusted hazard ratio (95% confidence interval) for 6-month all-cause mortality in patients with both biomarkers in the highest vs. lowest tertile was 9.67 (2.65-35.2). When cMyC was replaced with hs-cTnT, similar results were observed for hs-cTnT. In addition, the C-indices for addition of cMyC or hs-cTnT to the baseline model were similar (0.798 vs. 0.800, p = 0.94). In conclusion, similar to hs-cTnT, cMyC at admission may be a potent, independent predictor of 6-month all-cause mortality in patients without ACS treated at medical CICUs, and their prognostic abilities may be comparable. Combining cMyC or hs-cTnT with NT-proBNP may substantially improve early risk stratification of this population.
  • 高味良行, 丹羽若菜, 松橋和己, 天野健太郎, 秋田淳年, 山名孝治, 前川厚生, 村松崇, 井澤英夫, 高木靖
    日本冠疾患学会誌(Web), (Supplement), 2023  
  • Masataka Yoshinaga, Takashi Muramatsu, Hidetsugu Fujigaki, Kuniaki Saito, Hideo Izawa
    Fujita medical journal, 8(2) 65-66, May, 2022  
  • 松脇 佑次, 小林 昌義, 丹羽 若菜, 良永 真隆, 村松 崇, 井澤 英夫
    脈管学, 61(Suppl.) S247-S247, Oct, 2021  
More

Books and Other Publications

 5

Presentations

 10
More

Teaching Experience

 1
  • Apr, 2016 - Present
    Cardiology  (School of Medicine, Fujita Health University)

Professional Memberships

 10
More

Research Projects

 2

その他教育活動上特記すべき事項

 2
  • 件名（英語）
    第6回　心臓血管外科・循環器内科合同勉強会
    終了年月日（英語）
    2014/04/27
    概要（英語）
    講演：新しい冠動脈治療法 - 生体吸収性ステント -
  • 件名（英語）
    第50回藤田保健衛生大学医学部医学教育ワークショップ
    終了年月日（英語）
    2014/02/22
    概要（英語）
    ワークショップ「学生支援のスキルを向上させるために」に参加した。
To the list screen